ArticleJournal of Korean medical science2010
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Article in Journal of Korean medical science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation
Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review.BMC cancer · 2023Pooled it
- Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes.Medicine · 2016Trial
- Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.The Lancet. Oncology · 2010Trial
- Chemotherapy-induced oxidative injury in pediatric acute lymphoblastic leukemia: The role of N-acetylcysteine (Review).Biomedical reports · 2026Review
- Prevention of Anthracyclines and HER2 Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.Cancers · 2024Review
- Remote Ischemic Conditioning in Pediatric Cancer Patients Receiving Anthracycline Chemotherapy: A Sham-Controlled Single-Blind Randomized Trial.JACC. CardioOncology · 2023Article
- Benazepril hydrochloride protects against doxorubicin cardiotoxicity by regulating the PI3K/Akt pathway.Experimental and therapeutic medicine · 2021Article
- Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective.Cost effectiveness and resource allocation : C/E · 2020Article
- Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.Cardio-oncology (London, England) · 2019Review
- Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.Cancer research and treatment · 2019Article
- Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"Circulation research · 2018Article
- Response by Bernstein to Letter Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"Circulation research · 2018Article
- Protecting the heart in cancer therapy.F1000Research · 2018Review
- Late Cardiotoxicity: Issues for Childhood Cancer Survivors.Current treatment options in cardiovascular medicine · 2016Review
- Cardiotoxicity of anthracycline therapy: current perspectives.Archives of medical science : AMS · 2016Article
- Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.American journal of translational research · 2016Review
- Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.Current heart failure reports · 2015Review
- Treatment, behavioral, and psychosocial components of cardiovascular disease risk among survivors of childhood and young adult cancer.Journal of the American Heart Association · 2015Review
- Treatment-related cardiotoxicity in survivors of childhood cancer.Nature reviews. Clinical oncology · 2013Review
- Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.Antioxidants & redox signaling · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study attempted to assess the incidence and outcome of anthracycline cardiotoxicity and the role of dexrazoxane as a cardioprotectant in childhood solid tumors. The dexrazoxane group included 47 patients and the control group of historical cohort included 42. Dexrazoxane was given in the 10:1 ratio to doxorubicin. Fractional shortening and systolic and diastolic left ventricular diameters were used to assess the cardiac function. The median follow-ups were 54 months in the dexrazoxane group and 86 months in the control group. The mean cumulative doses of doxorubicin were 280.8+/-83.4 mg/m(2) in the dexrazoxane group and 266.1+/-75.0 mg/m(2) in the control group. The dexrazoxane group experienced significantly fewer cardiac events (27.7% vs. 52.4%) and less severe congestive heart failure (6.4% vs. 14.3%) than the control group. Thirteen cardiotoxicities including one cardiac death and 2 congestive heart failures occurred in the dexrazoxane group, and 22 cardiotoxicities including 2 cardiac deaths and 4 congestive heart failures, in the control group. Five year cardiac event free survival rates were 69.2% in the dexrazoxane group and 45.8% in the control group (P=0.04). Dexrazoxane reduces the incidence and severity of early and late anthracycline cardiotoxicity in childhood solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.